Gemtuzumab Ozogamicin

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Monitor 4 Mechanism-of-action 5 Notes 6 More General Terms 7 Additional Terms 8 References

Introduction

• Withdrawn from US market June 2010 [2]

Indications

• acute myeloid leukemia ( AML)

Monitor

• liver function tests, symptoms of hepatotoxicity [3]

Mechanism-of-action

• conjugate of recombinant humanized IgG4 kappa with cytotoxic tumor antibiotic calicheamicin
• specifically binds to the CD33 antigen expressed on leukemic blasts in over 80% of patients with acute myeloid leukemia ( AML)

Notes

• accelerated approval in 2000
• post-approval clinical trial failed to demonstrate benefit; increased mortality associated with receiving Mylotarg [2]

More General Terms

• monoclonal antibody
• recombinant protein
• antineoplastic agent (chemotherapeutic agent)

Additional Terms

• acute myeloid leukemia (AML)
• CD33; myeloid cell surface antigen CD33; sialic acid-binding Ig-like lectin 3; siglec-3; gp67 (SIGLEC3)

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 2000
2. FDA MedWatch Mylotarg (gemtuzumab ozogamicin): Market Withdrawal [1]
3. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: [2] (subscription needed) [3]

gemtuzumab ozogamicin (Mylotarg)